Latham & Watkins has advised Canaan and Brandon Capital as investors on the US$25 million Series B funding round of Pathios Therapeutics Limited (Pathios), a biotech company focused on the development of first-in-class therapies for cancer.
The round included participation from Canaan and Brandon Capital as existing investors, and new investment from Bristol Myers Squibb.
The Latham team was led by London corporate partner Shing Lo, with associate Toni Adejuyigbe.
Where the legal industry reads first.
Enjoyed this article? Get the biggest legal industry updates, deals, appointments, insights and expert interviews in your inbox, free.
No spam. Unsubscribe anytime.From Legal Desire
Is your firm the one being cited, or the one being skipped?
We ran the test. On several everyday legal questions, software companies are answering and law firms are not. We help firms fix that, and we build the technology behind the practice.
The advising firms, the named deal team, the value and the parties, with every other announced deal by the same firms and lawyers. Open the deal record
